

GENOMMA LAB SECOND QUARTER 2025



Genomma Lab.®
Internacional



Genomma Lab Internacional Announces Results for the Second Quarter 2025

Mexico City, July 23, 2025 – Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) (“Genomma” or “the Company”), today announced its results for the second quarter of 2025. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with International Financial Reporting Standards (IFRS), unless otherwise noted.

Comments from our CEO, Marco Sparvieri

“Genomma’s second quarter sales grew +0.5%, or +5.5% excluding Argentina, reflecting a significant Argentine peso depreciation and a weak beverage season in Mexico. Importantly, the company’s profitability remained solid, with +4.4% EBITDA growth, margin expanding +89 bps to 23.8%, and a proforma net income increase of +16.6% (excluding non-cash FX related effects). These profitability levels and a 7-day improvement in cash conversion cycle drove a +64.6% free-cash-flow increase for the trailing twelve months. As the company navigates macroeconomic headwinds in 2025, we remain intently focused on executing our growth projects while maintaining an average EBITDA margin of 24% through our ongoing productivity program.”

Q2 2025 Financial Summary

The following table provides a summary of the Company’s Income Statement, in millions of Mexican pesos.

	Q2 2025	% sales	Q2 2024	% sales	% var
Net Sales	4,676.4	100.0%	4,651.5	100.0%	+0.5%
Like-for-like Sales ⁽¹⁾					+0.3%
Gross Profit	2,969.4	63.5%	2,977.7	64.0%	(0.3)%
Operating Income	1,030.6	22.0%	983.3	21.1%	+4.8%
EBITDA⁽²⁾	1,112.9	23.8%	1,065.8	22.9%	+4.4%
Net Income	355.0	7.6%	631.6	13.6%	(43.8)%
Proforma Net Income ⁽³⁾	667.8	14.3%	572.7	12.3%	+16.6%
EPS	0.35		0.63		(43.8)%
Proforma EPS⁽³⁾	0.67		0.57		+16.6%

(1) Like-for-like (“LFL”) Sales are Net Sales expressed in constant currency and excludes the hyperinflationary subsidiary

(2) EBITDA defined as operating income before depreciation and amortization

(3) Proforma Net Income = Net Income – Foreign Exchange Result – Inflationary Result from Monetary Position

Net sales: Increased +0.5%, or +5.5% excluding Argentina, impacted by an -18.3% Argentine peso depreciation and a weak beverage season in Mexico, partially offset by robust growth in the US, Brazil, Central America and Andean cluster.

EBITDA: Reached a 23.8% margin; a +4.4% increase reflecting a significant +89 basis-point expansion driven by manufacturing cost efficiencies, a favorable sales mix and successful company-wide productivity initiatives.

Net income: Decreased -43.8% impacted by a significant non-cash FX loss and an inflationary loss from the Company’s monetary position in its hyperinflationary subsidiary.

Proforma net income: When excluding non-cash FX related effects, proforma net income increased +16.6% reflecting a higher margin due to increased operating income and lower net interest expenses.

Proforma EPS: When excluding non-cash effects, EPS stood at Ps. 0.67 per share; a +16.6% increase.

Regional Review per Business Unit

Genomma's strategy to focus on core brands continues to resonate on the Company's results, reflected in 75% of sales growing above inflation and 67% of sales maintaining or gaining market share. The following table provides a summary of regional sales per business unit for the three-month period ended June 30, 2025.

Business Unit	Mexico			Latam			U.S.			Total		
	Q2 2025	Q2 2024	Δ%	Q2 2025	Q2 2024	Δ%	Q2 2025	Q2 2024	Δ%	Q2 2025	Q2 2024	Δ%
Beverages	426.6	582.5	(26.8)%	185.4	168.3	10.1%	132.8	64.5	106.0%	744.7	815.3	(8.7)%
OTC	869.2	784.1	10.9%	1,013.2	1,204.0	(15.8)%	176.3	228.2	(22.7)%	2,058.7	2,216.3	(7.1)%
Personal Care	697.1	694.2	0.4%	845.6	664.4	27.3%	152.6	122.6	24.5%	1,695.4	1,481.2	14.5%
Infant Nutrition	177.6	138.7	28.1%	-	-	n.a.	-	-	n.a.	177.6	138.7	28.1%
Total	2,170.6	2,199.5	(1.3)%	2,044.2	2,036.7	0.4%	461.7	415.3	11.2%	4,676.4	4,651.5	0.5%

The following sales review compares results of the current quarter with the same quarter of the prior year in MXN, unless otherwise stated:

Mexico: Net sales declined -1.3%, impacted by a weak beverage season due to lower-than-normal temperatures in this market, partially offset by a double-digit increase in OTC sales with strong performance and market share gains in Analgesics and Cough & Cold. Personal Care saw a double-digit increase in Haircare, mixed Skincare results, and continued double-digit sell-out growth from the Asepxia relaunch. Infant Nutrition grew double digits on improved fill rates and market share gains in key formulas. Suerox maintained its market share with sell-out down -3.7%, outperforming the isotonic category's -20% year-to-date decline in this market. Route expansion in the northwest was accelerated to mitigate weather impacts.

The EBITDA margin increased to 24.6%, a +207-basis point expansion due to productivity gains.

Latam (ex Arg): Net sales increased 10.5% driven by robust growth in Brazil, Central America, and the Andean Cluster. EBITDA margin including Argentina reached 24.7%, a -44-basis point decrease mainly due to hyperinflation accounting related effects.

Argentina: Net sales declined -14.2% to Ps. 717.1 million, driven by hyperinflationary accounting adjustments following an -18.7% Argentine peso depreciation. Local currency sales grew in line with inflation, with solid unit share gains in Ibu 400, Treg, and Suerox, partly offset by a tough comparison from the prior-year Tarifol 1-gram government subsidy.

US: Net sales increased +11.2% led by a favorable FX while local currency sales grew +0.7% reflecting continued beverage expansion in the region and robust performance in haircare despite ongoing disruption in US Hispanic consumption. The EBITDA margin reached 15.8%, a 204 basis-point increase due to productivity gains.



Working Capital & Free Cash Flow

The following tables provide a summary of the Company's working capital.

	Q2 2025	Q2 2024	Δ	Q1 2025	Δ
Receivable days	100	104	-4	103	-3
Payable days	96	103	-7	104	-8
Inventory days	111	121	-10	117	-6
CCC	115	122	-7	116	-1

Cash Conversion Cycle (CCC): reached 115 days, a 7-day improvement driven by a 10-day decrease in inventories post-beverage season and a 4-day reduction in receivables.

A decrease in days payable reflects the Company's transition to in-house OTC manufacturing in Mexico.

Free Cash Flow (FCF): increased 64.6% to Ps. 2,705.3 million during the trailing-twelve months (TTM) compared to the same period of last year. The Company converted 14.4% of the TTM Net Sales into free cash flow.

Capital Allocation

Dividends. On July 1st, 2025, the Company paid a cash dividend of \$0.200000 Mexican pesos per share on common stock paid during the quarter, totaling Ps. 200 million. Genomma intends to continue quarterly dividend payments.

Share buybacks. 4.6 million shares repurchased during the quarter totaling Ps. 104.1 million.


CAPEX: Investments in manufacturing equipment totaled Ps. 86.6 million in Q2 2025, including investments related to the commissioning of the Company's new Suerox line.

Key Debt Ratios

EBITDA / Debt Service: 4.96x

Net Debt / EBITDA: 1.04x

Cash Conversion Cycle




Figures in days

Days of Accounts Receivable (DSO)

	Q2 2025	Q2 2024	Q1 2025
Mexico	116	106	111
Latam	91	108	98
US	63	73	85
Consolidated	100	104	103

FREE CASH FLOW TTM

Figures in MXN millions



Relevant Events

[Genomma Lab successfully issued the LAB 25 and LAB 25-2 unsecured bonds \(Cebures\)](#)

[Genomma Lab Internacional Informs Total Prepayment Of "Lab 23" Unsecured Local Bond \(Cebures\)](#)

[Genomma Lab Internacional Announces Twelfth Dividend Payment](#)

Conference Call

Date: Thursday, July 24, 2025

Time: 1:00 p.m. ET | 11:00 a.m. Mexico City Time

Webcast Registration: [Genomma's Q2 2025 Earnings Call](#)

Participants:

Marco Sparvieri, CEO
Antonio Zamora, CFO
Christianne Ibanez, IRO

Contact Information:

Investor Relations

Christianne Ibanez
Daniel Suarez

Tel: +52 (55) 5081-0075
investor.relations@genommalab.com

InspIR Group

Barbara Cano

Tel: +1 (646) 452-2334
barbara@inspirgroup.com

Sell-side Analyst Coverage

As of July 23, 2025 "LABB" is covered by 9 sell-side analysts at the following brokerages: Actinver Casa de Bolsa, Banco Itaú BBA, BBVA Bancomer, BTG Pactual US Capital, GBM Grupo Bursátil Mexicano, Grupo Financiero Banorte, J.P. Morgan Securities, Monex Grupo Financiero and Vector Casa de Bolsa.

About

Genomma Lab Internacional, S.A.B. de C.V. is one of the leading pharmaceutical and personal care products companies in Mexico with an increasing international presence. Genomma Lab develops, sells and markets a broad range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. Genomma Lab relies on the combination of a successful new product development process, a consumer-oriented marketing, a broad retail distribution network and a low-cost, highly flexible operating model. Genomma Lab's shares are listed on the Mexican Stock Exchange under the ticker "LAB B" (Bloomberg: LABB:MM).



Member of
Dow Jones
Sustainability Indices
Powered by the S&P Global CSB

Note on Forward-Looking Statements

This report may contain certain forward-looking statements and information relating to the Company that reflect the current views and/or expectations of the Company and its management with respect to its performance, business and future events. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like "believe," "anticipate," "expect," "envisages," "will likely result," or any other words or phrases of similar meaning. Such statements are subject to a number of risks, uncertainties and assumptions. We caution you that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in this presentation and in oral statements made by authorized officers of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. Risks and uncertainties include, but are not limited to: risks related to the impact of the COVID19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays, supply chain disruptions and other impacts to the business, or on the Company's ability to execute business continuity plans as a result of the COVID-19 pandemic, economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products attained by competitors; challenges inherent in new product development; the ability of the Company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws; changes in behavior and spending patterns of purchasers of products and services; financial instability of international economies and legal systems and sovereign risk. A further list and descriptions of these risks, uncertainties and other factors can be found within the Company's related filings with the Bolsa Mexicana de Valores. Any forward-looking statement made in this release speaks only as of the date of this release. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V. AND SUBSIDIARIES

CONSOLIDATED STATEMENT OF INCOME

For the three and six months ended June 30, 2025 and 2024

Thousands of Mexican pesos	Q2					6M				
	2025	% Sales	2024	% Sales	Δ%	2025	% Sales	2024	% Sales	Δ%
Net Sales	4,676,435	100.0%	4,651,495	100.0%	0.5%	9,082,761	100.0%	8,848,815	100.0%	2.6%
Cost of goods sold	(1,707,020)	(36.5)%	(1,673,795)	(36.0)%	2.0%	(3,346,025)	(36.8)%	(3,131,444)	(35.4)%	6.9%
Gross Profit	2,969,415	63.5%	2,977,700	64.0%	(0.3)%	5,736,736	63.2%	5,717,371	64.6%	0.3%
Selling, general and administrative expenses	(1,883,464)	(40.3)%	(1,918,346)	(41.2)%	(1.8)%	(3,604,133)	(39.7)%	(3,724,231)	(42.1)%	(3.2)%
Other income (expense)	26,985	0.6%	6,408	0.1%	321.1%	28,146	0.3%	8,205	0.1%	243.0%
EBITDA	1,112,936	23.8%	1,065,762	22.9%	4.4%	2,160,749	23.8%	2,001,345	22.6%	8.0%
Depreciation and amortization	(82,299)	(1.8)%	(82,478)	(1.8)%	(0.2)%	(169,489)	(1.9)%	(160,812)	(1.8)%	5.4%
Income from operations	1,030,637	22.0%	983,284	21.1%	4.8%	1,991,260	21.9%	1,840,533	20.8%	8.2%
Interest expense	(194,272)	(4.2)%	(208,556)	(4.5)%	(6.8)%	(414,374)	(4.6)%	(409,172)	(4.6)%	1.3%
Interest income	33,297	0.7%	9,007	0.2%	269.7%	61,543	0.7%	43,968	0.5%	40.0%
Foreign exchange result	(249,764)	(5.3)%	128,714	2.8%	(294.0)%	(266,889)	(2.9)%	41,825	0.5%	(738.1)%
Inflationary result from monetary position	(63,063)	(1.3)%	(69,778)	(1.5)%	(9.6)%	(113,533)	(1.2)%	(97,491)	(1.1)%	16.5%
Comprehensive financing income (cost)	(473,802)	(10.1)%	(140,613)	(3.0)%	237.0%	(733,253)	(8.1)%	(420,870)	(4.8)%	74.2%
Associated company	0	0.0%	0	0.0%	n.a.	0	0.0%	0	0.0%	n.a.
Income before income taxes	556,835	11.9%	842,671	18.1%	(33.9)%	1,258,007	13.9%	1,419,663	16.0%	(11.4)%
Income tax expense	(201,869)	(4.3)%	(211,026)	(4.5)%	(4.3)%	(404,322)	(4.5)%	(355,923)	(4.0)%	13.6%
Net income from continuous operations	354,966	7.6%	631,645	13.6%	(43.8)%	853,685	9.4%	1,063,740	12.0%	(19.7)%
Results from discontinuous operations (Marzam)	0	0.0%	0	0.0%	n.a.	0	0.0%	(59,989)	(0.7)%	(100.0)%
Consolidated net income	354,966	7.6%	631,645	13.6%	(43.8)%	853,685	9.4%	1,003,751	11.3%	(15.0)%

GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V. AND SUBSIDIARIES

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As of June 30, 2025 and 2024 and December 31, 2024

Thousands of Mexican pesos	As of June 30,			As of December 31,	
	2025	2024	Δ%	2024	Δ%
ASSETS					
Current assets					
Cash and equivalents and restricted fund	2,587,887	1,233,360	109.8%	2,379,112	8.8%
Clients - Net	5,233,232	4,842,027	8.1%	4,444,414	17.7%
Recoverable Taxes	1,577,438	1,587,398	(0.6)%	1,492,538	5.7%
Other accounts receivable*	838,046	777,009	7.9%	702,175	19.4%
Inventory - Net	2,124,652	2,088,052	1.8%	2,176,087	(2.4)%
Prepaid expenses	927,686	955,781	(2.9)%	872,205	6.4%
Total current assets	13,288,941	11,483,627	15.7%	12,066,531	10.1%
Non-current assets					
Trademarks	5,610,246	5,211,297	7.7%	5,926,549	(5.3)%
Investment in shares	0	0	n.a.	0	n.a.
Discontinued Operations	0	550,000	(100.0)%	0	n.a.
Building, properties and equipment – Net	3,604,365	3,455,618	4.3%	3,526,885	2.2%
Deferred income tax, assets and others	1,675,006	1,240,499	35.0%	1,466,152	14.2%
Assets by right of use	65,968	43,773	50.7%	31,686	108.2%
Total non-current assets	10,955,585	10,501,187	4.3%	10,951,272	0.0%
TOTAL ASSETS	24,244,526	21,984,814	10.3%	23,017,803	5.3%
LIABILITIES AND STOCKHOLDERS' EQUITY					
Current Liabilities					
Short-term debt and Current portion of long-term debt	2,236,480	1,526,335	46.5%	1,364,832	63.9%
Suppliers	1,843,403	1,773,987	3.9%	1,738,018	6.1%
Other current liabilities	3,001,202	2,635,365	13.9%	3,277,059	(8.4)%
Income tax payable	185,193	206,861	(10.5)%	158,509	16.8%
Total current Liabilities	7,266,278	6,142,548	18.3%	6,538,418	11.1%
Non-current liabilities					
Long-term debt securities	3,384,413	3,183,906	6.3%	3,187,798	6.2%
Long-term loans with financial institutions	1,579,133	1,662,589	(5.0)%	1,877,012	(15.9)%
Deferred income tax and other long term liabilities	779,311	417,573	86.6%	529,719	47.1%
Payable dividends to shareholders	0	0	n.a.	0	n.a.
Total non-current Liabilities	5,742,857	5,264,068	9.1%	5,594,529	2.7%
TOTAL LIABILITIES	13,009,135	11,406,616	14.0%	12,132,947	7.2%
Stockholders' equity					
Contributed Capital	1,825,350	1,861,857	(2.0)%	1,825,350	0.0%
Retained earnings	12,014,828	11,511,808	4.4%	11,511,687	4.4%
Cumulative translation effects of foreign subsidiaries	(785,850)	(976,343)	(19.5)%	(653,102)	20.3%
Repurchased shares - Net	(1,821,275)	(1,821,462)	(0.0)%	(1,801,417)	1.1%
Fair value through profit OCI	2,338	2,338	0.0%	2,338	0.0%
Total Stockholders' Equity	11,235,391	10,578,198	6.2%	10,884,856	3.2%
TOTAL EQUITY AND LIABILITIES	24,244,526	21,984,814	10.3%	23,017,803	5.3%

GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V. AND SUBSIDIARIES

CONSOLIDATED STATEMENT OF CASH FLOWS

For the three months ended June 30, 2025 and 2024

Thousands of Mexican pesos	Q2		Δ%
	2025	2024	
Cash and cash equivalents beginning of period	2,157,025	1,142,126	88.9%
Consolidated Net Income	354,966	631,645	(43.8)%
Charges to results with no cash flow:			
Depreciation and amortization	92,043	59,845	53.8%
Income tax	201,868	211,026	(4.3)%
Accrued interest and others	236,651	245,036	(3.4)%
Changes in Working Capital:			
Clients - Net	(102,365)	(154,915)	(33.9)%
Recoverable VAT	(58,048)	86,486	(167.1)%
Inventories	(58,579)	(60,029)	(2.4)%
Suppliers	(52,023)	(165,617)	(68.6)%
Other current assets	75,290	(307,984)	(124.4)%
Paid income tax	(149,014)	(57,741)	158.1%
Other current liabilities	(31,257)	(75,674)	(58.7)%
Net cash generated (used) in operating activities	509,532	412,078	23.6%
Investing activities:			
Investment in fixed assets	(86,566)	(16,097)	437.8%
Resources from financial instruments	(14,675)	7,086	(307.1)%
Sales of equipment	2,945	3,361	(12.4)%
Other asset acquisitions	(36,376)	(58,666)	(38.0)%
Interest collected	33,263	9,025	268.6%
Net cash generated (used) in investing activities	(101,409)	(55,291)	83.4%
Financing activities:			
Payments of borrowings with financial institutions	(2,091,270)	(1,710,466)	22.3%
Loans with financial and securities institutions	2,400,000	1,787,798	34.2%
Interest paid	(191,575)	(209,613)	(8.6)%
Net Stock repurchase	36,075	68,455	(47.3)%
Payment of liabilities for lease	(12,600)	(28,770)	(56.2)%
Dividends paid to shareholders	0	(208,189)	(100.0)%
Net cash used in financing activities	140,630	(300,785)	(146.8)%
Net increase in cash and cash equivalents before foreign exchange adjustments coming from international operations and inflationary affects cash	548,753	56,002	879.9%
Foreign exchange and inflationary effects from international operations	(117,891)	35,232	(434.6)%
Accumulated cash flow at the end of the period	2,587,887	1,233,360	109.8%
Less - restricted fund	17,128	16,299	5.1%
Cash and cash equivalents at end of period balance for operation	2,570,759	1,217,061	111.2%

ANNEX

EXCLUSION OF IAS 29 AND IAS 21 EFFECTS

For the three months and trailing twelve months ended June 30, 2025 and 2024

	Reported		Δ%	2025		2024		Excl. IAS 29 & 21		
	Q2 2025	Q2 2024		Inflation Effect (IAS 29)	Conversion Effect (IAS 21)	Inflation Effect (IAS 29)	Conversion Effect (IAS 21)	Q2 2025	Q2 2024	Δ%
Net Sales	4,676.4	4,651.5	0.5%	63.4	(186.8)	131.8	36.5	4,799.8	4,483.2	7.1%
EBITDA	1,112.9	1,065.8	4.4%	12.2	(56.3)	43.3	12.9	1,157.0	1,009.6	14.6%
EBITDA Margin	23.8%	22.9%						24.1%	22.5%	
Net Income	355.0	631.6	(43.8)%	(130.2)	(26.3)	(107.7)	9.8	511.4	729.6	(29.9)%
Net Margin	7.6%	13.6%						10.7%	16.3%	

	Reported		Δ%	2025		2024		Excl. IAS 29 & 21		
	12M Q2 2025	12M Q2 2024		Inflation Effect (IAS 29)	Conversion Effect (IAS 21)	Inflation Effect (IAS 29)	Conversion Effect (IAS 21)	12M Q2 2025	12M Q2 2024	Δ%
Net Sales	18,840.8	16,767.2	12.4%	451.0	(212.2)	1,182.1	(1,875.4)	18,602.0	17,460.5	6.5%
EBITDA	4,429.7	3,600.2	23.0%	142.2	(63.9)	376.9	(706.0)	4,351.4	3,929.3	10.7%
EBITDA Margin	23.5%	21.5%						23.4%	22.5%	
Net Income	1,881.1	1,357.5	38.6%	(668.7)	(31.0)	(393.5)	(375.2)	2,580.7	2,126.2	21.4%
Net Margin	10.0%	8.1%						13.9%	12.2%	

ANNEX

REGIONAL SALES PER BUSINESS UNIT

For the three months and six months ended June 30, 2025 and 2024

Business Unit	Mexico			Latam			U.S.			Total		
	Q2 2025	Q2 2024	Δ%	Q2 2025	Q2 2024	Δ%	Q2 2025	Q2 2024	Δ%	Q2 2025	Q2 2024	Δ%
Beverages	426.6	582.5	(26.8)%	185.4	168.3	10.1%	132.8	64.5	106.0%	744.7	815.3	(8.7)%
OTC	869.2	784.1	10.9%	1,013.2	1,204.0	(15.8)%	176.3	228.2	(22.7)%	2,058.7	2,216.3	(7.1)%
Personal Care	697.1	694.2	0.4%	845.6	664.4	27.3%	152.6	122.6	24.5%	1,695.4	1,481.2	14.5%
Infant Nutrition	177.6	138.7	28.1%	-	-	n.a.	-	-	n.a.	177.6	138.7	28.1%
Total	2,170.6	2,199.5	(1.3)%	2,044.2	2,036.7	0.4%	461.7	415.3	11.2%	4,676.4	4,651.5	0.5%

Business Unit	Mexico			Latam			U.S.			Total		
	YTD Q2 2025	YTD Q2 2024	Δ%	YTD Q2 2025	YTD Q2 2024	Δ%	YTD Q2 2025	YTD Q2 2024	Δ%	YTD Q2 2025	YTD Q2 2024	Δ%
Beverages	981.4	985.8	(0.4)%	443.0	305.6	45.0%	273.8	124.6	119.7%	1,698.2	1,416.0	19.9%
OTC	1,687.0	1,615.2	4.4%	1,936.9	2,040.9	(5.1)%	329.7	456.1	(27.7)%	3,953.5	4,112.2	(3.9)%
Personal Care	1,254.9	1,304.9	(3.8)%	1,585.0	1,465.6	8.1%	288.8	260.7	10.8%	3,128.6	3,031.1	3.2%
Infant Nutrition	302.3	289.5	4.4%	-	-	n.a.	-	-	n.a.	302.3	289.5	4.4%
Total	4,225.7	4,195.4	0.7%	3,964.9	3,812.1	4.0%	892.2	841.4	6.0%	9,082.7	8,848.8	2.6%



S&P Global ESG Score
"62"
Record high from 58 last year

MSCI
ESG RATINGS



Third improvement
in last 4 yrs



EMPRESA
SOCIALMENTE
RESPONSABLE

19th consecutive
year awarded



+100,000
Medicines donated during
Q2 2025



2024 ESG Annual
Report
[Read here](#)